Table 1.

Baseline characteristics

		Fractional dose group (n=126)	Standard dose group (n=124)
Median age at enrolment (IQR), years		36 (27–45)	38 (30–45)
Sex
	Female	73 (58%)	56 (45%)
	Male	53 (42%)	68 (55%)
Seropositive to yellow fever at baseline*		2 (2%)	2 (2%)
Previous flavivirus infection		0	1 (<1%)
Geometric mean CD4+ T-cell count (SD), cells per mL		549 (266)	561 (261)

Data are n (%) unless otherwise specified. All participants were stage 1 HIV WHO clinical stage.

^*Defined as 50% plaque reduction neutralisation test ≥10.